AbbVie's Drug ABT-414 Has Been Granted Orphan Drug Status by Both the FDA and EMA for the Treatment of Glioblastoma Multiforme

AbbVie Granted Orphan Drug Status for Glioblastoma Therapy

In Regulation & Government by CecileLeave a Comment

abbvie logo

AbbVie’s Drug  ABT-414 Has Been Granted Orphan Drug Status by Both the FDA and EMA for the Treatment of Glioblastoma Multiforme

The pharmaceutical company AbbVie has been granted coveted orphan drug status by both the European Medicines Agency and the US Food and Drug Administration for its drug ABT-414 for the treatment of glioblastoma multiforme.

Glioblastoma multiforme is one of the most common types of brain tumours that afflicts people. With very low rates of survival of under 10%, the pressure to develop a drug to remedy the condition is high.

The drug will now move into phase 2 trials, whilst receiving marketing and development incentives from the government as a result of its orphan status.

Read more about it here: Abbvie receives EMA and FDA orphan drug designation for investigational compound abt-414 in the treatment of glioblastoma multiforme

Leave a Comment